Janet Jill Hopkins Sells 2,534 Shares of Aura Biosciences, Inc. (NASDAQ:AURA) Stock

Aura Biosciences, Inc. (NASDAQ:AURA) insider Janet Jill Hopkins sold 2,534 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $7.75, for a total value of $19,638.50. Following the sale, the insider now owns 269,794 shares in the company, valued at approximately $2,090,903.50. The trade was a 0.93 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Aura Biosciences Stock Performance

AURA stock opened at $7.65 on Wednesday. The stock’s 50 day simple moving average is $8.07 and its 200 day simple moving average is $8.76. Aura Biosciences, Inc. has a fifty-two week low of $6.63 and a fifty-two week high of $12.38. The company has a market cap of $382.12 million, a P/E ratio of -4.42 and a beta of 0.29.

Analysts Set New Price Targets

AURA has been the topic of several research analyst reports. HC Wainwright restated a “buy” rating and set a $22.00 target price on shares of Aura Biosciences in a research report on Thursday, November 14th. Lifesci Capital raised Aura Biosciences to a “strong-buy” rating in a research note on Friday, January 31st. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $23.00.

Institutional Trading of Aura Biosciences

Institutional investors and hedge funds have recently modified their holdings of the stock. Barclays PLC raised its stake in shares of Aura Biosciences by 256.5% in the third quarter. Barclays PLC now owns 61,010 shares of the company’s stock worth $544,000 after purchasing an additional 43,897 shares during the last quarter. State Street Corp raised its stake in shares of Aura Biosciences by 3.7% in the third quarter. State Street Corp now owns 754,803 shares of the company’s stock worth $6,725,000 after purchasing an additional 26,841 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Aura Biosciences by 4.1% in the third quarter. Geode Capital Management LLC now owns 1,008,827 shares of the company’s stock worth $8,990,000 after purchasing an additional 39,379 shares during the last quarter. Wellington Management Group LLP purchased a new stake in shares of Aura Biosciences in the third quarter worth approximately $1,037,000. Finally, Franklin Resources Inc. raised its stake in shares of Aura Biosciences by 14.8% in the third quarter. Franklin Resources Inc. now owns 1,668,960 shares of the company’s stock worth $15,571,000 after purchasing an additional 215,597 shares during the last quarter. 96.75% of the stock is owned by hedge funds and other institutional investors.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.